A

Altimmune

D
ALT
USD
0.15
(2.0188%)
Market Closed
107,396.00
Volume
-1.25
EPS
-
Div Yield
-4.650307
P/E
538,717,808.58
Market Cap
Today
2.0188%
1 Week
6.836%
1 Month
0.664%
6 Months
-13.173%
12 Months
163.194%
Year To Date
-32.652%
All Time
-99.129%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
8.85235E-5
(0.2311%)
USD

Title:
Altimmune

Sector:
Healthcare
Industry:
Biotechnology
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Do you need help or have a question?
Contact Us